Project Grant HT9425261E222
- Federal Grant Award Summary The University of Illinois received a $750,000 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the three-year period from May 1, 2026, through April 30, 2029. The award supports research focused on unlocking new therapeutic potential of aprepitant, an FDA-approved drug, through investigation of immunogenic cell death induction and immune-mediated tumor regression mechanisms in advanced...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded a $1,465,443 Project Grant to the University of Illinois, with performance from September 1, 2025, through August 31, 2028, under the Military Medical Research and Development program (CFDA 12.420). The grant supports research on "The Promise of Epigenetic Therapy for Refractory Testicular Germ Cell Tumors," advancing innovative biomedical solutions for cancer treatment. The research will be conducted at the...
- The University of Illinois was awarded a $1,235,845 Project Grant from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) to leverage data science methods to deliver individualized treatment effects in metastatic hormone sensitive prostate cancer. The award, with a performance period from August 15, 2025 to August 14, 2028, supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader...
- Summary The University of Illinois received a $1.25M Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective July 1, 2026 through June 30, 2029. The award supports research into novel cholesterol-targeting therapies for inflammatory breast cancer, to be conducted at the university's Chicago, Illinois location. This three-year initiative aligns with the DHA's mission to transform healthcare for service members and...
- The Defense Health Agency awarded a $1,398,689 Project Grant to the University of Illinois under the Military Medical Research and Development program (CFDA 12.420) to support research on "Pharmacologic Downregulation of SOX2 to Enhance Efficacy of Anti-AR Therapies in Prostate Cancer". The project aims to investigate methods for improving the effectiveness of anti-androgen therapies for prostate cancer through modulating the SOX2 protein. The award will fund this 3-year research...
- Federal Project Grant Award Summary The University of Illinois received a $400,814 project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective October 1, 2025 through September 30, 2028. The award funds development of a Portable Panretinal Imager for Automated Detection of Retinal Detachment in Austere Environments. This research initiative aligns with DHA's mission to support hypothesis-driven biomedical innovation...
- Federal Project Grant Award Summary The University of Illinois has been awarded $555,100 by the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for a three-year project commencing August 1, 2025 and concluding July 31, 2028. The project, titled "Testicular Germ Cell Tumors as a Sentinel Cancer of PFAS Exposure," supports advanced biomedical research investigating the relationship between perfluoroalkyl and polyfluoroalkyl substances...
- Federal Grant Award Summary The University of Chicago received a $869,193 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective July 1, 2025 through June 30, 2028. The award funds research to identify the pathogenesis of monosomy 7 in bone marrow failure (BMF), a basic biomedical research initiative aligned with the program's objective to transform healthcare for service members and the American public through...
- This $1,599,997.00 Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports advanced biomedical research at the University of Illinois aimed at transforming healthcare for military service members, veterans, and the broader public. The research, spanning basic, applied, and translational investigations, focuses on innovative approaches to address critical health challenges across diverse medical domains such as cancer,...
- Federal Grant Award Summary The University of Illinois received a $779,173 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period October 1, 2025 through September 30, 2028. The award supports the development of a portable panretinal imager designed to enable automated detection of retinal detachment in austere environments. This research and development initiative addresses a critical military health priority...
The University of Illinois received a $1.7M Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) awarded June 1, 2026, with performance through May 31, 2029. The award funds research investigating SOX2-driven homologous recombination as a therapeutic strategy to overcome radiation resistance in metastatic prostate cancer. The research will be conducted at the University of Illinois' Chicago, Illinois location and represents the DHA's investment in hypothesis-driven biomedical research designed to advance innovative medical solutions for both military service members and the general public. Under this three-year funding period, the University of Illinois will deliver research and development services including mechanistic investigation of SOX2 protein's role in cancer cell radiation resistance, development of potential therapeutic approaches targeting homologous recombination pathways, and translational research outputs to advance treatment options for metastatic prostate cancer. This award aligns with the Military Medical Research and Development program's emphasis on oncology research and therapeutic development, with deliverables expected to include research findings, preclinical data, and scientific publications advancing the understanding and treatment of radiation-resistant prostate cancer.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.7m | 5/29/26 |